Like a Game of Chess, Every Move Matters: The Role of Antibodies in the Myasthenia Gravis Treatment Landscape

Treatment of myasthenia gravis (MG) is complicated and must be highly individualized based on patients’ varied symptoms and disease pathophysiology and their individual preferences and priorities. Until very recently, clinicians and patients have had to make difficult decisions whether to sacrifice either efficacy or tolerability when selecting treatments. New treatments have the potential of being both effective and well tolerated. The following Academic Highlights presents an overview of a recent webinar in which the faculty discussed the current treatment landscape for MG and promising investigational treatments that may become available in the future.